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Volume 58, Number 4 Abstracts 1149diagnostic imaging, and access-related procedures including those pertain-
ing to access maturation. These events were designated as occurring within
either the ﬁrst or second year of functional access patency. Current proce-
dural terminology codes were used to calculate the unadjusted Medicare,
or “national average,” reimbursement in 2012 US dollars for these events
as outpatient hospital encounters. Bivariate analysis using linear modeling
and one-way analysis of variance was used to assess differences in mean
cost.
Results: RCFs and BCFs had higher 1-year functional patency costs
in females than in males ($19,257 vs $15,089 and $17,275 vs $13,819)
regardless of age. This remained statistically signiﬁcant with respect to 2-
year functional patency ($48,362 vs $42,372 and $43,361 vs $37,651).
RCF and BCF were costlier in patients over the age of 70 than BBF
($23,492 vs $22,984 vs $14,089) regardless of gender over the ﬁrst year
of access functional patency. This difference remained at 2 years as well
($53,251 vs $56,261 vs $39,372). Among females over age 70, the cost
of maintaining BBF was less expensive than in males or younger females
($13,247 vs $16,668 or $15,827) during the ﬁrst year as well as the second
year ($33,374 vs $44,726 or $44,324). All mentioned differences demon-
strated statistical signiﬁcance with a P value of <.05.
Conclusions: Sex, age, and anatomic location may correlate with cost
differences in maintaining 1- and 2-year functional patency of AVFs. These
ﬁnancial differences may further be stratiﬁed by patient demographics.
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Objectives: Atherosclerosis (AthSc) is escalated by the excessive accu-
mulation of oxidized low density lipoprotein (OxLDL). A new class of
nanopolymers, termed nanolipoblockers (NLB), has previously demon-
strated inhibition of OxLDL uptake by macrophages. Using an ex vivo
human carotid plaque model for targeted intervention with NLB offers
potential new mechanisms of AthSc treatment.
Methods: Carotid plaques were sectioned and incubated in culture
medium at 37C. Samples were treated with the NLBs of different polymer
chemistries and 5 mg/mL oxLDL to evaluate NLB binding to plaque and to
assess inhibition of plaque recruitment of OxLDL and effect on inﬂamma-
tion. Samples were digested, homogenized, ﬁltered, and ﬂuorescence quan-
tiﬁed by ﬂow cytometry and confocal microscopy to identify plaque
composition, NLB, and oxLDL uptake.
Results: Plaque cells were identiﬁed in the specimen showing high
levels of NLB binding, merely within 5 minutes, with an increase in uptake
in a chemistry-dependent manner after 24 hours (Fig 1). NLBs lowered
inﬂammatory markers in the presence of oxLDL. Furthermore, NLBs
caused a marked decrease in the uptake of OxLDL in plaque (Fig 2).
Conclusions: AthSc plaques could be targeted through NLB inter-
vention via a reduction in inﬂammatory substrates and multicellular OxLDLFig 1.uptake inhibition. This ex vivo model and the NLBs provide a promising
therapeutic strategy for the management of active AthSc.
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Objectives: Impending changes to hospital reimbursement has
focused attention on the signiﬁcant impact of unplanned hospital readmis-
sions on both patients and providers alike. Vascular surgery patients have
high readmission rates and identiﬁcation of high-risk groups that may be
amenable to targeted interventions is an important strategy for readmission
prevention. This study aimed to determine predictors of unplanned read-
mission and develop a risk score for predicting readmissions after vascular
surgery.
Methods: The National Surgical Quality Improvement Program
database for 2011 was queried for major vascular surgical procedures. The
primary end point was unplanned 30-day readmissions. The data was
randomly split into two-thirds for development and one-third for validation.
Multivariate logistic regression was used to create and validate a point score
system to predict unplanned readmissions.
Results: Overall 24,310 patients were included, with 2464 readmis-
sions (10.1%). A point based scoring system was developed based on
multivariate logistic regression for factors predictive for readmission
(Table). The scoring system developed included procedure type (open
abdominal aortic aneurysm ¼ 3 points, peripheral intervention 5 points,
amputation ¼ 1 point), graft failure prior to discharge (5 points), veno-
thromboembolism prior to discharge (4 points), discharge destination
(facility that was home ¼ 3-points, new facility or rehab ¼ 2 points), Black
race (1 point), nonelective presentation (1 point), pulmonary (2 points),
cardiac (2 points), renal (1 point) comorbidities, chronic steroid use (2
points), hypoalbuminemia (2 points), anemia (2 points), diabetes (1
point), bleeding disorder (1 point), operative time $150 minutes (1
point), and bleeding disorder (1 point). The point score was used to
stratify patients into three groups: low risk (0-3 points) with a readmission
rate of 5.4%, moderate risk (4-7 points) with a readmission rate of 8.6%,
and high risk ($8 points) with a readmission rate of 16.4%. The model had
good predictive ability (c-statistic ¼ 0.67).
Conclusions: Using patient, operative, and predischarge events, this
novel vascular surgery speciﬁc readmission score accurately identiﬁed
patients at high risk for 30-day unplanned readmission. This model could
help direct discharge and home health care resources to patients at high
risk, ultimately reducing readmissions and improving efﬁciency.
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Covariate OR 95% CI P valueBlack/African American (ref ¼ white) 1.21 1.04-1.41 .014
Procedure (ref ¼ carotid) Ref Ref <.001
EVAR 1.06 0.85-1.32 .616
Open AAA 1.53 1.18-1.98 .001
Other 1.49 1.24-1.80 <.001
Peripheral 1.93 1.59-2.34 <.001
Amputation 1.24 0.99-1.53 .057
Disposition (reference ¼ home) Ref Ref <.001
Nursing facility (prior) 1.54 1.13-2.10 .007
Facility/rehab (new) 1.30 1.12-1.50 <.001
Hypoalbuminemia 1.35 1.18-1.55 <.001
Pulmonary comorbidity 1.35 1.17-1.56 <.001
Cardiac comorbidity 1.28 1.13-1.44 <.001
Renal comorbidity 1.24 1.02-1.50 .033
VTE prior to discharge 1.83 1.00-3.36 .050
Graft failure prior to discharge 2.07 1.03-4.134 .040Scientiﬁc Session III: Peripheral
Risk Factors for Below-the-Knee Amputation Failure Requiring
Above-the-Knee Revision
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Objectives: The purpose of this study was to identify risk factors that
impact below-the-knee (BKA) failures requiring proximal revision to an
above-the-knee amputation (AKA).
Methods: All consecutive major lower extremity amputations or revi-
sions in vascular patients between 2009 and 2010 were identiﬁed. Medical
records were retrospectively reviewed for patient demographics, comorbid-
ities, amputation level, wound-healing, survival, and anatomic data (from
angiography and duplex examinations). Patients who healed their BKA
were compared with those requiring a proximal revision to an AKA. Statistical
analysis was performed with SAS System 9.1.3 (SAS Institute Inc, Cary, NC).
Results: Major lower extremity amputations or revisions were per-
formed on 247 limbs in 218 patients (age 66.7 6 12.2 years, 51% male,
87% African American). BKA was performed on 157 limbs (64%) with heal-
ing achieved in 114 (73%) and failure to heal in 42 (27%), of which 26 BKAs
(17%) required revision to an AKA. Women (58% vs 35%; P < .05), patients
with rest pain (15.4% vs 2.8%; P < .05), history of cardiac intervention or
surgery (50% vs 27%; P < .05), lower pre-albumin (9.3 6 2.5 mg/dL vs
13.1 6 7.8 mg/dL; P < .05) and patients with dementia (19.2% vs 6.4%;
P < .05) were more likely to require BKA to AKA revision. Preoperative
angiographic data was available for 69 (60%) of the healed BKAs and 17
(65%) of the BKA to AKA revisions. Ipsilateral common iliac artery stenosis
greater than 50% (18% vs 1.5%; P < .05), superﬁcial femoral artery occlusion
(70% vs 23%; P < .05), popliteal artery occlusion (47.1% vs 14.5%; P < .05)
and the combination of popliteal occlusion with no tibial runoff (29.4% vs
4.4%, P < .05) were each associated with BKA failures. Arterial duplex
data was available for 32 (28%) of the healed BKAs and six (23%) of the
BKAs to AKA revisions. Peak systolic velocities were signiﬁcantly lower
and below normal thresholds in the BKA failures at the external iliac artery
(P < .05), common femoral artery (P < .05), distal superﬁcial femoral artery
(P < .05), and popliteal artery (P < .05). Median survival was not signiﬁ-
cantly different between the two groups (4.0 vs 3.1 years).
Conclusions: Patients requiring a BKA to AKA revision have identiﬁ-
able risk factors that could be used to predict healing at a particular level and
obviate additional morbidity from subsequent revisions. Long-term survival
does not appear to be negatively impacted by amputation revisions.
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Objectives: While cilostazol is commonly used as an adjunct
following peripheral vascular interventions (PVI), its efﬁcacy remains uncer-
tain. We assessed the effect of cilostazol on outcomes following PVI using
meta-analytic techniques.Methods: We searched MEDLINE (1946-2012), Cochrane
CENTRAL (1996-2012), and trial registries for studies comparing cilosta-
zol in combination with antiplatelet therapy to antiplatelet therapy alone
following PVI. Treatment effects were reported as pooled risk/hazard ratios
using random effects models.
Results: Two randomized trials and four retrospective cohort studies
met inclusion criteria (total n ¼ 1522). Across studies, mean age ranged
from 66-76 years, the majority of patients were male (59%-82%), and
mean follow-up ranged from 18-37 months. Pooled estimates demonstrated
that the addition of cilostazol was associated with decreased restenosis (RR,
0.71; 95% CI, 0.60-0.84; P < .001,), improved amputation-free survival
(HR, 0.63; 95% CI, 0.47-0.85; P ¼ .002), improved limb salvage (HR,
0.42; 95% CI, 0.27-0.66; P < .001), and improved freedom from target
lesion revascularization (RR, 1.36; 95% CI, 1.14-1.61; P < .001) (Fig).
There was no signiﬁcant reduction in mortality among those receiving cil-
ostazol (RR, 0.73; 95% CI, 0.45-1.19; P ¼ .21).
Conclusions: The addition of cilostazol to standard therapy following
PVI is associated with a reduced risk of restenosis, amputation and target
lesion revascularization in our meta-analysis of six studies. Consideration
of cilostazol as a medical adjunct after PVI is warranted, presuming these
ﬁndings are broadly generalizable.
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Objectives: The purpose of this study was to compare contemporary
endovascular with surgical revascularization for ALI.
Methods: Consecutive patients with ALI treated with endovascular
(ER) or surgical revascularization (OR) between 2005 and 2011 were
identiﬁed and reviewed. Procedural success and outcomes were com-
pared between the two groups. Limb salvage and survival were assessed
using time-to-event methods, including Kaplan-Meier estimation and
competing-risks regression models.
Results: One-hundred ﬁfty-four limbs were treated in 147 patients
in the ER group, compared with 330 limbs in 296 patients in the OR
group. Patient characteristics, severity of ischemia, and indications for
intervention are presented in the Table. The mean follow-up was 14
months. Overall technical success was achieved in 80.5% (ER) vs 88.6%
(OR) (P ¼ .019). Thirty-day mortality rate was 5.4% (ER) and 13.2%
(OR) (P ¼ .013). Amputation rates were 6.5% (ER) vs13.3% (OR) at 30
days (P ¼ .027), and 13.0% (ER) and 19.7% (OR) at 1 year (P ¼ .075).
The primary patency was 57% (ER) and 53% (OR) at 1 year (P ¼ .301).
Rutherford class 2 ischemia represented the majority of our patients,
where overall technical success was 79.9% (ER) vs 91.5% (OR) (P ¼ .001).
Technical success in this class was higher with OR when performed for
a failed bypass (94.7% OR vs 75% ER; P ¼ .001), but with similar 1-year
amputation rates (25.0% OR vs 23.1% ER; P ¼ .84). Technical success was
comparable between the two groups for patients treated for embolic ALI
or in situ thrombosis, as were the amputation rates at 30 days and 1 year (P
¼ NS). Predictors of limb loss by life table analysis included coronary
artery disease (SHR ¼ 2.24; P ¼ .005) and end stage renal disease/dialysis
(SHR ¼ 2.76; P ¼ .031). Predictors of death by life table analysis included
age (SHR ¼ 1.02; P ¼ .001), end-stage renal disease (SHR ¼ 5.67; P <
.001), cancer (SHR ¼ 1.48; P ¼ .02), and rhabdomyolysis (SHR ¼ 3.07;
P < .01).
Conclusions: Patients presenting with Rutherford class 2 ALI are
commonly treated with endovascular or surgical revascularization with
